Skip to main content
Premium Trial:

Request an Annual Quote

SynapDx Raises $15.4M

NEW YORK (GenomeWeb News) – Autism diagnostics firm SynapDx today said that it raised $15.4 million.

Google Ventures led the round with Foundation Medical Partners also a new investor. Founding investors North Bridge Venture Partners and General Catalyst Partners also participated in the round.

The funding will be used to support Lexington, Mass.-based SynapDx as it develops a blood-based diagnostic test for autism spectrum disorder. The test is designed to help clinicians identify children with autism earlier than can be currently diagnosed.

In conjunction with the financing, Google's Andrew Conrad was appointed to SynapDx's board. Conrad was the chief scientific officer of Laboratory Corporation of America and co-founder of its National Genetics Institute.

In February, LabCorp made a $2 million investment into SynapDx. SynapDx raised $6 million in a Series A1 financing round in December.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more